James Schaub
2021
In 2021, James Schaub earned a total compensation of $832.2K as EVP and Chief Operating Officer at RVL Pharmaceuticals plc, a 38% decrease compared to previous year.
Compensation breakdown
| Bonus | $90,000 |
|---|---|
| Option Awards | $312,268 |
| Salary | $418,462 |
| Other | $11,506 |
| Total | $832,236 |
Schaub received $418.5K in salary, accounting for 50% of the total pay in 2021.
Schaub also received $90K in bonus, $312.3K in option awards and $11.5K in other compensation.
Rankings
In 2021, James Schaub's compensation ranked 9,370th out of 12,415 executives tracked by ExecPay. In other words, Schaub earned more than 24.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,370 out of 12,415 | 25th |
Division Manufacturing | 4,155 out of 5,505 | 25th |
Major group Chemicals And Allied Products | 1,835 out of 2,375 | 23rd |
Industry group Drugs | 1,627 out of 2,096 | 22nd |
Industry Pharmaceutical Preparations | 1,208 out of 1,546 | 22nd |
Source: SEC filing on April 25, 2022.
Schaub's colleagues
We found three more compensation records of executives who worked with James Schaub at RVL Pharmaceuticals plc in 2021.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019